tbuckley/cabot-search huggingface dataset:
FRI0284 Anti-Srp-Associated Autoimmune Myopathy: Younger Age at Onset Is Associated with More Severe Disease and Worse Outcome
Authors: I. Pinal-Fernandez, C. Parks, E. Tiniakou, M. Albayda, J. Paik, A. Lahouti, M. Casal-Dominguez, K. Pak, W. Huang, T.E. Lloyd, S. Danoff, L. Casciola-Rosen, L. Christopher-Stine, A.L. Mammen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Anti-SRP autoantibodies are associated with an immune-mediated necrotizing myopathy. Although some anti-SRP-positive patients respond well to therapy, others continue to have active disease and persistent weakness despite treatment<sup>1,2</sup>. <h3>Objectives</h3> Here, we studied a large cohort of anti-SRP-positive patients to identify factors associated with disease severity and clinical improvement. <h3>Methods</h3> All anti-SRP positive patients in the Johns Hopkins Myositis Cohort from 2002 to 2015 were included in the study. Longitudinal information regarding proximal muscle strength, creatine kinase levels, and immunosuppressive therapy were recorded at each visit. Univariate and multivariate analyses using multilevel regression models were used to assess prognostic factors influencing the recovery of strength over time. <h3>Results</h3> Thirty-seven anti-SRP-positive patients (78% female) were included. Older age at onset was associated with greater strength at the first visit (p=0.02) and at all subsequent visits (p=0.002) independent of sex, race, disease duration and immunosuppressive treatment. Younger patients had worse outcomes, with less strength at the last visit (p=0.003) independent of disease duration, sex, and race. Although we could not definitively study response to treatment in this longitudinal cohort, rituximab appeared to be effective in 13 of 17 patients who received it (76%, 95%CI: 53% 90%). Younger patients often required continuous and intensive therapy with multiple immunosuppressive drugs to sustain full strength even two years after the onset of the disease. <h3>Conclusions</h3> In anti-SRP-associated myositis, a younger age at disease onset is associated with more severe weakness and worse outcomes. Rituximab may be an effective treatment in both young and old patients. <h3>References</h3> Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 2015;10:61. Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol 2012;24:602–8. <h3>Disclosure of Interest</h3> None declared
Genetic Evidence That CD154 (CD40 Ligand) Plays a Pathophysiologic Role in the Systemic Coagulopathy Associated with Murine Models of Experimental Metastasis and Endotoxemia.
Authors: Susan B. Ingersoll, Ali Amirkhosravi, Florian Langer, Jamie Walker, Todd Meyer, Mildred Amaya, John L. Francis
Journal: Blood (2004)
A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma
Authors: William I. Bensinger, Robert Vescio, Cristina Gasparetto, Elber S. Camacho, Rajneesh Nath, Christina L. Gomes, David D. Smith, Jatin J. Shah, Brian G. M. Durie
Journal: Blood (2014)
Treatment of Diffuse Large B-Cell Lymphoma with Rituximab, Intensive Induction and High-Dose Consolidation: The Final Analysis of the Czech Lymphoma Study Group (CLSG) R-MegaCHOP-ESHAP-BEAM (R-MEB) Trial.
Authors: Marek Trneny, Robert Pytlik, David Belada, Katerina Kubackova, Ingrid Vasova, Alice Sykorova, Tomas Kozak, Jan Pirnos, Milan Matuska, Ingrid Bolomska, Jana Pribylova, Marie Trnkova, Michaela Hamouzova, Pavel Klener
Journal: Blood (2007)
Bortezomib Impairs Myeloma Cells (MM) Homologous Recombination Through Inhibition of the E2-Ubiquitin-Conjugating Enzyme UBC13
Authors: Paola Neri, Li Ren, Jordan Johnson, Kathy J Gratton, Erin Stebner, Carolyn J Owen, Peter Duggan, Douglas A. Stewart, Nizar Bahlis
Journal: Blood (2011)
Interpretation and Use of Another Statin Guideline
Authors: Philip Greenland, Robert O. Bonow
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Identification of RIZ1 Targets Involvedin Erythroid Differentiation of K562 Human Erythroleukemia Cells Using Surface-Enhanced Laser Desorption Ionization Time-Of-Flight Mass Spectrometry (SELDI).
Authors: Naoto Takahashi, Matthew Brainbridge, Stuart A. Scott, Ryo Ichinohasama, Stephen E. Sanche, Wei-Feng Dong, John F. DeCoteau, C. R. Geyer
Journal: Blood (2004)
Proliferation and Differentiation of Thrombocyte Progenitors In the Liver and the Spleen In Xenopus Laevis Under the Stimulation of Thrombopoietin
Authors: Yuta Tanizaki, Ayaka Tahara, Sayaka Kinoshita, Motoki Yamauchi, Mizue Meguro, Shun Maekawa, Kazumichi Nagasawa, Takako Ishida-Iwata, Miyako Obuchi-Shimoji, Nami Nogawa-Kosaka, Takashi Kato
Journal: Blood (2010)
Bowel Diseases in the Tropics: Cholera, Dysenteries, Liver Abscess and Sprue.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dasatinib In Children and Adolescents with Relapsed or Refractory Leukemia: Results of the CA180018 Phase 1 Dose-Escalation Study of the Innovative Therapies for Children with Cancer (ITCC) Consortium
Authors: C. Michel Zwaan, Carmelo Rizzari, Francoise Mechinaud, Donna L Lancaster, Pamela R. Kearns, Thomas Lehrnbecher, Vincent H. J. van der elden, H. Berna Beverloo, Monique L. den Boer, Rob Pieters, Julie Rosenberg, Robert Herdlicka, Dominique Derreumaux, Shruti Agrawal, André Baruchel
Journal: Blood (2010)
Prognostic Factors for Survival and Progression to Acute Myeloid Leukemia in Patients with Lower-Risk Myelodysplastic Syndromes. A New Scoring System
Authors: Jose F Falantes, Cristina Calderón, Ildefonso Espigado, Dora Alonso, Antonio Martín Noya, Estrella Carrillo, Maria Luz Martino, Isabel Montero, Jose González, Jose Antonio Pérez-Simón
Journal: Blood (2011)
Improved Anticancer Photothermal Therapy Using the Bystander Effect Enhanced by Antiarrhythmic Peptide Conjugated Dopamine‐Modified Reduced Graphene Oxide Nanocomposite
Authors: Jiantao Yu, Yu‐Hsin Lin, Lingyan Yang, Chih‐Ching Huang, Liliang Chen, Wen‐Cheng Wang, Guan‐Wen Chen, Junyan Yan, Saranta Sawettanun, Chia‐Hua Lin
Journal: Advanced Healthcare Materials (2016)

Despite tremendous efforts toward developing novel near-infrared (NIR)-absorbing nanomaterials, improvement in therapeutic efficiency remains a formidable challenge in photothermal cancer therapy. This study aims to synthesize a specific peptide conjugated polydopamine-modified reduced graphene oxide (pDA/rGO) nanocomposite that promotes the bystander effect to facilitate cancer treatment using NIR-activated photothermal therapy. To prepare a nanoplatform capable of promoting the bystander effect in cancer cells, we immobilized antiarrhythmic peptide 10 (AAP10) on the surface of dopamine-modified rGO (AAP10-pDA/rGO). Our AAP10-pDA/rGO could promote the bystander effect by increasing the expression of connexin 43 protein in MCF-7 breast-cancer cells. Because of its tremendous ability to absorb NIR absorption, AAP10-pDA/rGO offers a high photothermal effect under NIR irradiation. This leads to a massive death of MCF-7 cells via the bystander effect. Using tumor-bearing mice as the model, it is found that NIR radiation effectively ablates breast tumor in the presence of AAP10-pDA/rGO and inhibits tumor growth by ≈100%. Therefore, this research integrates the bystander and photothermal effects into a single nanoplatform in order to facilitate an efficient photothermal therapy. Furthermore, our AAP10-pDA/rGO, which exhibits both hyperthermia and the bystander effect, can prevent breast-cancer recurrence and, therefore, has great potential for future clinical and research applications.
Cancer stem cell metabolism: a potential target for cancer therapy
Authors: Abhijeet Deshmukh, Kedar Deshpande, Frank Arfuso, Philip Newsholme, Arun Dharmarajan
Journal: Molecular Cancer (2016)

Cancer Stem cells (CSCs) are a unipotent cell population present within the tumour cell mass. CSCs are known to be highly chemo-resistant, and in recent years, they have gained intense interest as key tumour initiating cells that may also play an integral role in tumour recurrence following chemotherapy. Cancer cells have the ability to alter their metabolism in order to fulfil bio-energetic and biosynthetic requirements. They are largely dependent on aerobic glycolysis for their energy production and also are associated with increased fatty acid synthesis and increased rates of glutamine utilisation. Emerging evidence has shown that therapeutic resistance to cancer treatment may arise due to dysregulation in glucose metabolism, fatty acid synthesis, and glutaminolysis. To propagate their lethal effects and maintain survival, tumour cells alter their metabolic requirements to ensure optimal nutrient use for their survival, evasion from host immune attack, and proliferation. It is now evident that cancer cells metabolise glutamine to grow rapidly because it provides the metabolic stimulus for required energy and precursors for synthesis of proteins, lipids, and nucleic acids. It can also regulate the activities of some of the signalling pathways that control the proliferation of cancer cells. This review describes the key metabolic pathways required by CSCs to maintain a survival advantage and highlights how a combined approach of targeting cellular metabolism in conjunction with the use of chemotherapeutic drugs may provide a promising strategy to overcome therapeutic resistance and therefore aid in cancer therapy.
THU0056 Women, Men, and Rheumatoid Arthritis: Radiographic Progression over Ten Years in The Current Millennium
Authors: J. Asikainen, T. Rannio, H. Kautiainen, P. Hannonen, T. Sokka
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Radiographs of hands and feet represent an objective outcome measure of rheumatoid arthritis (RA). Joint damage is a result of cumulative disease activity over years. Unlike other clinical measures, radiographic damage is caused mainly by disease inflammatory activity. Therefore, radiographs are a proper measure to analyze whether RA behaves differently in women and men over time. <h3>Objectives</h3> To compare radiographic progression in women and men over 10 years after diagnosis of early RA. <h3>Methods</h3> All 1046 patients who were diagnosed with RA in 1997 – 2005 at a single rheumatology center were scheduled for a 10 year follow-up with radiographs of hands and feet at years 0, 2, 5, and 10. Larsen score (0 - 100) was employed including MCPs, wrists and 2–5 MTP joints. Radiographic progression over 10 years was calculated and compared between women and men. <h3>Results</h3> Among 1046 patients (66% women, mean age 58, 60% seropositive, 13% with erosions at baseline), 5-year radiographs were available in 85% and 10-year radiographs in 71% of patients. A 5-year radiographic progression was similar between women and men: among 539 seropositive patients the median (IQR) Larsen score was 2 (0, 6) in 359 women and 2 (0, 7) in 180 men. In 346 seronegative patients the figures were 0 (0, 2) and 0 (0, 2) in 245 women and 101 men, respectively. Overall, 50% of seropositive women and 52% of seropositive men showed erosions and in seronegative patients the respective proportions were 17% and 23%. Also the 10-year radiographic progression was similar between women and men (Figure 1). Among 480 seropositive patients, the median (IQR) Larsen score was 4 (0, 10) in 333 women and 4 (1, 9) in 147 men. In 263 seronegative patients the figures were 0 (0, 2) and 0 (0, 3) in 187 women and 76 men, respectively. Overall, 59% of seropositive women and 63% of men showed erosions and in seronegative patients the proportions were 21% and 28%, respectively. Among seropositive women vs men similar proportion had been treated with various anti rheumatic medications including 90% vs 87% MTX, 22% vs 29% subcutaneous MTX, 75% vs 84% SSZ, 76% vs 71% HCQ, 17% vs 16% LEF, 14% vs 12% im gold, 78% vs 77% Pred, and 22% vs 20% biologic agents. Mortality (a total of 15% of women and 30% of men died over 10 years) was the main reason for missing data. <h3>Conclusions</h3> Radiographic progression is similar in women and men who are treated for RA in the current millennium. <h3>Disclosure of Interest</h3> None declared
CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies
Authors: Brian J Lannutti, Sarah A. Meadows, Adam Kashishian, Bart Steiner, Sarah May, Amy J. Johnson, Roger G. Ulrich, Albert Yu, Michael W. Gallatin, John C. Byrd, Kamal D. Puri, Neill A. Giese
Journal: Blood (2008)
A Quality of Life Assessment of Ablative Allogeneic Bone Marrow Transplant (BMT) Recipients One and Twelve Months after Transplant.
Authors: Brian Bolwell, Linda McLellan, Larry Foster, Lisa Rybicki, Ronald M. Sobecks, Brad Pohlman, Steve Andresen, Elizabeth Kuczkowski, Mary Serafin, Karen Sands, Jennifer Kosar, Stacey Brown, Jennifer Bates, Mikkael Sekeres, Jane Dabney, Erin Welsh, Matt Kalaycio
Journal: Blood (2005)
Early Experience with Clofarabine Pre-Conditioning Prior to Full Intensity or Reduced Toxicity Allogeneic Stem Cell Transplantation: A Promising New Therapy for the Treatment of Refractory Acute Leukaemia
Authors: Deborah S. Richardson, Amy Publicover, Kate Hill, Carol Hurlock, Joan Newman, Nikki McKeag, Sara Main, Harriet Launders, Kim H. Orchard
Journal: Blood (2012)
Should local government run the NHS?
Authors: Andrew Furber
Journal: BMJ (2016)

A white paper published by the Conservative government in 1944 proposed that a new National Health Service should be managed by local authorities.1 The Labour Party was split on the matter, but after its general election victory in 1945 Aneurin Bevan proposed a plan favouring nationalisation of all hospitals. And so the NHS was born.

Nearly 70 years later the role of local government in the NHS is once again being debated. The integration of services delivered through local authorities and the NHS is under way in every part of the United Kingdom. In England several NHS clinical commissioning groups are now led by local government officers. So should the NHS be run by local authorities, and would it be better?



Aneurin Bevan marked the birth of the NHS …
Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL
Authors: Rebecca L. Elstrom, Leandro Cerchietti, Peter Martin, Richard R. Furman, ShaoNing Yang, Jia Ruan, Paul Christos, Morton Coleman, Amelyn Rodriguez, Madhu Mazumdar, Ari Melnick, John P. Leonard
Journal: Blood (2012)
CTP-221, a Deuterated S-Enantiomer of Lenalidomide, Possesses Significantly Enhanced Immunomodulatory and Anti-Proliferative Properties Relative to the R-Enantiomer and to Racemic Lenalidomide.
Authors: Lijun Wu, Ara M. Aslanian, Julie F. Liu, Kristine Hogan, Roger Tung
Journal: Blood (2012)
Progressive Disappearance of Anti-HBs and Reverse Seroconversion after allo-HSCT in Patients with Previous HBV Infection.
Authors: Masahiro Onozawa, Satoshi Hashino, Takeshi Kondo, Shuichi Ota, Sumiko Kobayashi, Junji Tanaka, Masahiro Imamura, Masahiro Asaka
Journal: Blood (2004)
Explaining the Excess Risk of Multiple Myeloma in African-Americans
Authors: Wendy Cozen, Amie E. Hwang, Sikander Ailawadhi, Seema Singhal, Carol Ann Huff, Leon Bernal-Mizrachi, Brian C-H Chiu, Elizabeth E Brown, Edward Peters, Karen Pawlish, Mohrbacher Ann, Cathryn H. Bock, Christopher Haiman, Daniel O. Stram, Kristin A Rand, Michael H. Tomasson, Nidhi Jain, David J. Van Den Berg, John J. Graff, Graham A Colditz, Todd M Zimmerman, Jeffrey Zonder, Robert Z. Orlowski, Sagar Lonial
Journal: Blood (2012)
Abstract 16242: Symptomatic Bradycardia in the Elderly: Compliance With ACLS Guidelines and in-Hospital Outcome
Authors: Federico M Cintora, Ricardo Perez de la Hoz, Sandra Swieszkowski, Analia Aquieri, Guillermo Lopez Soutric, Alejandro Lakowsky, Paulino Alvarez, Eduardo Sampo
Journal: Circulation (2010)

Objective: to assess if compliance with ACLS Guidelines for the Management of Bradycardia (ACLS-GMB) in a cohort of elderly patients admitted to coronary care unit (CCU) with diagnosis of symptomat...
Influence of Hematopoietic Cell Lysate Vaccinations and Dendritic Cell Enriched Marrow Grafts on Engraftment after Nonmyeloablative Hematopoietic Stem Cell Transplantation.
Authors: Sandra Lange, Bettina Lange, Heike Vogel, Volker Weirich, Inken Hilgendorf, Daniel Wolff, Nicole Hofmeister, Mathias Freund, Christian Junghanss
Journal: Blood (2005)
On the Yellow Brick Road to Platelet GP IIb-IIIa (Integrin αIIbβ3) Activation.
Authors: Naohide Watanabe, Jaewon Han, C. James Lim, Alessandra Soriani, Wilma Puzon-McLaughlin, Esther M. LaFuente, Vassiliki A. Boussiotis, Mark H. Ginsberg, Sanford J. Shattil
Journal: Blood (2006)
Steroid injections through the eardrum reduce dizziness in Meniere’s disease, study finds
Authors: Susan Mayor
Journal: BMJ (2016)

We apologise for not having noticed earlier Adrion and colleagues' comments on our study comparing the effectiveness of intratympanic Methylprednisolone to Gentamicin in refractory Ménière's disease [1], covered by the BMJ [2].Contrary to our expectations, both drugs were equally effective in controlling vertigo (primary outcome).Adrion's primary concerns were, (i) that negative studies pose the problem of "not knowing how to interpret the non-significant results in a clinically relevant way" and, (ii) the lack of a power calculation for the primary outcome.
Colonoscopic extraction of a chicken wishbone stuck in the sigmoid colon, identified as diverticulitis: the patient’s and doctor’s wish comes true
Authors: Vladimir Milivojevic, Ivan Rankovic, Bojan Djukic, Miodrag Krstic, Tomica Milosavljevic
Journal: Endoscopy (2016)

A 75-year-old woman attended our clinic presenting with a 7-day history of nausea, left lower quadrant abdominal pain, and fever. Laboratory data revealed leukocytosis (14 500 white blood cells/mL) and an elevated C-reactive protein level (28 mg/L). Palpable abdominal pain in the left lower quadrant and a raised temperature (38 °C) were found on physical examination. Findings were negative for melena, blood per rectum, weight loss, and change in stool frequency. An abdominal X-ray showed bowel distension with one significant air–fluid level, without pneumoperitoneum. Besides renal calculosis the abdominal ultrasonography was unremarkable. Based on the clinical examination and laboratory findings, the patient's initial diagnosis was diverticulitis. A course of broad-spectrum antibiotic therapy was initiated.